Clinical Trial: A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies

U.S., Dec. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07308132) titled 'A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies' on Dec. 15.

Brief Summary: The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 (Part 1: Dose Escalation) and to further characterize the safety and clinical activity of JNJ-95566692 at the putative RP2D(s) (Part 2: Dose Expansion).

Study Start Date: Jan. 16, 2026

Study Type: INTERVENTIONAL

Condition: Lymphoma, Non-Hodgkin

Intervention: DRUG: JNJ-95566692

JNJ-95566692 will be administered subcutaneously.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Janssen Resea...